Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 29, 2016

View Archived Issues

VCE-004.8 shows promise for the treatment of scleroderma

Facio receives funding from the Dutch FSHD Foundation

Esteve and UAB expand gene therapy platform with therapies for Sanfilippo B and Hunter's syndromes

Baxalta seeks FDA approvals for Adynovate for use in pediatric patients and surgical settings

PharmaMar starts phase II trial of microtubule inhibitor PM-184 in breast cancer

Heat Biologics updates progress of phase II trial of HS-410 for non-muscle invasive bladder cancer

Hydra Biosciences patents TrpC5 antagonists

Nuevolution discloses RORgamma modulators

Eolas Therapeutics develops orexin receptor modulators

Changzhou Runnor Biological Technology describes EGFR mutant inhibitors

Bristol-Myers Squibb initiates phase I/IIa study of BMS-986205 with nivolumab in advanced cancers

Ortho-McNeil-Janssen Pharmaceuticals divulges GluN2B receptor inhibitors

Encouraging phase I data for Biota's RSV fusion inhibitor BTA-585

Gilead's Descovy receives positive CHMP opinion for HIV infection

Aurora Biopharma secures grant for trials of CAR T-cell therapy for glioblastoma and osteosarcoma

EMA CHMP issues positive opinion for ixekizumab for plaque psoriasis

Daiichi Sankyo initiates phase I trial of U3-1784 for solid tumors

Takeda's ixazomib receives orphan drug designation in Japan for multiple myeloma

FDA approves Afinitor for progressive, nonfunctional GI and lung neuroendocrine tumors

EMA committee recommends E.U. approval of Alprolix to treat hemophilia B

Rare Disease Day: SONIA trials to clarify the potential of nitisinone in treating alkaptonuria

EMA's CHMP recommends approval of Opdivo for two new indications

Intravaginal prasterone shows promise for female sexual dysfunction

CHMP recommends approval of Taiho's Lonsurf for metastatic colorectal cancer

Genentech's lebrikizumab achieves primary endpoint in one of two phase III trials in severe asthma

EMA committee hands down positive opinion for Viekirax + Exviera label expansion

FDA approves Gazyva for use in follicular lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...